JP2024116386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024116386A5 JP2024116386A5 JP2024098418A JP2024098418A JP2024116386A5 JP 2024116386 A5 JP2024116386 A5 JP 2024116386A5 JP 2024098418 A JP2024098418 A JP 2024098418A JP 2024098418 A JP2024098418 A JP 2024098418A JP 2024116386 A5 JP2024116386 A5 JP 2024116386A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662303979P | 2016-03-04 | 2016-03-04 | |
| US62/303,979 | 2016-03-04 | ||
| US201662348116P | 2016-06-09 | 2016-06-09 | |
| US62/348,116 | 2016-06-09 | ||
| PCT/US2017/020650 WO2017152044A1 (en) | 2016-03-04 | 2017-03-03 | Compositions and methods for muscle regeneration using prostaglandin e2 |
| JP2018546415A JP2019513010A (ja) | 2016-03-04 | 2017-03-03 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| JP2022089405A JP2022116259A (ja) | 2016-03-04 | 2022-06-01 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089405A Division JP2022116259A (ja) | 2016-03-04 | 2022-06-01 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024116386A JP2024116386A (ja) | 2024-08-27 |
| JP2024116386A5 true JP2024116386A5 (enExample) | 2024-12-16 |
Family
ID=59743257
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546415A Withdrawn JP2019513010A (ja) | 2016-03-04 | 2017-03-03 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| JP2022089405A Pending JP2022116259A (ja) | 2016-03-04 | 2022-06-01 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| JP2024098418A Pending JP2024116386A (ja) | 2016-03-04 | 2024-06-19 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546415A Withdrawn JP2019513010A (ja) | 2016-03-04 | 2017-03-03 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| JP2022089405A Pending JP2022116259A (ja) | 2016-03-04 | 2022-06-01 | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240415849A1 (enExample) |
| EP (2) | EP4538365A3 (enExample) |
| JP (3) | JP2019513010A (enExample) |
| KR (2) | KR102481354B1 (enExample) |
| CN (2) | CN109072186B (enExample) |
| AU (3) | AU2017225999B2 (enExample) |
| BR (1) | BR112018017228A2 (enExample) |
| CA (1) | CA3014667A1 (enExample) |
| DK (1) | DK3423067T3 (enExample) |
| ES (1) | ES3039622T3 (enExample) |
| WO (1) | WO2017152044A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| US10159566B2 (en) * | 2016-09-26 | 2018-12-25 | Novartis Ag | Heat tunable intraocular lens |
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| CN110573154A (zh) | 2017-02-06 | 2019-12-13 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| AU2018249956B2 (en) | 2017-04-07 | 2024-05-23 | Board Of Regents Of The Univeristy Of Texas | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
| WO2018227134A1 (en) * | 2017-06-09 | 2018-12-13 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing or treating muscle conditions |
| SG11202105345TA (en) | 2018-11-21 | 2021-06-29 | Univ Case Western Reserve | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN114051410A (zh) * | 2019-04-30 | 2022-02-15 | 白雁生物技术公司 | 包含分离的线粒体为有效成分的预防或治疗肌炎的药物组合物 |
| BR112021023952A2 (pt) * | 2019-06-11 | 2022-01-18 | Univ Leland Stanford Junior | Métodos de rejuvenescimento de tecido envelhecido pela inibição de 15-hidroxiprostaglandina desidrogenase (15-pgdh) |
| KR20220079563A (ko) * | 2019-09-16 | 2022-06-13 | 인스티튜트 오브 주올로지, 차이니즈 아카데미 오브 사이언스 | 조직 재생을 위한 방법 및 조성물 |
| EP4164638A4 (en) * | 2020-06-11 | 2024-06-19 | The Board of Trustees of the Leland Stanford Junior University | REJUVENATION OF AGED TISSUES AND ORGANS BY INHIBITION OF THE DEGRADING ENZYME PGE2, 15-PGDH |
| CN116457014A (zh) * | 2020-10-23 | 2023-07-18 | 莱兰斯坦福初级大学评议会 | 通过抑制前列腺素降解酶15-pgdh提升线粒体生物合成和功能 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927213A (en) * | 1973-07-10 | 1975-12-16 | American Home Prod | Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents |
| US5143842A (en) | 1988-11-01 | 1992-09-01 | The University Of Colorado Foundation, Inc. | Media for normal human muscle satellite cells |
| US5409911A (en) | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
| US5833978A (en) * | 1995-03-16 | 1998-11-10 | Universite Laval | Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success |
| ATE327751T1 (de) | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz |
| MXPA03004623A (es) * | 2000-11-27 | 2003-09-05 | Pfizer Prod Inc | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. |
| US6410591B1 (en) | 2001-05-08 | 2002-06-25 | Allergan Sales, Inc. | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| CA2454584C (en) | 2001-07-23 | 2009-09-22 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient |
| US6841573B2 (en) * | 2002-11-27 | 2005-01-11 | Molecular Nutrition | Use of arachidonic acid as a method of increasing skeletal muscle mass |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| US7169807B2 (en) | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
| WO2006016695A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤 |
| US7696235B2 (en) | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
| PE20071230A1 (es) | 2006-02-09 | 2008-01-16 | Schering Corp | Combinaciones y metodos de inhibidores del vhc |
| EP1999255A2 (en) * | 2006-03-24 | 2008-12-10 | The Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| JP4583500B2 (ja) | 2006-07-28 | 2010-11-17 | ファイザー・プロダクツ・インク | Ｅｐ２作動薬 |
| AU2008331597B2 (en) | 2007-11-29 | 2013-11-28 | Allergan, Inc. | Substituted cyclopentanes having prostaglandin activity |
| US8871752B2 (en) * | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
| CN102057037B (zh) | 2008-04-11 | 2014-06-18 | 学校法人庆应义塾 | 平滑肌干细胞的分离方法 |
| US20130236433A1 (en) * | 2010-11-11 | 2013-09-12 | Keith A. Webster | Methods, compositions, cells, and kits for treating ischemic injury |
| US10111907B2 (en) * | 2011-12-02 | 2018-10-30 | Fate Therapeutics, Inc. | Methods of treating ischemia |
| WO2013158649A1 (en) * | 2012-04-16 | 2013-10-24 | Case Western Reserve University | Compositions and methods of modulating 15-pgdh activity |
| US20130331389A1 (en) * | 2012-06-11 | 2013-12-12 | National Cheng Kung University | Methods and Compositions for Cardiomyocyte Replenishment by Endogenous and Progenitor Stem Cells |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| EP3057973B1 (en) * | 2013-10-15 | 2019-09-04 | Case Western Reserve University | Compositions comprising a 15-pgdh inhibitor for the healing of wounds |
-
2017
- 2017-03-03 JP JP2018546415A patent/JP2019513010A/ja not_active Withdrawn
- 2017-03-03 AU AU2017225999A patent/AU2017225999B2/en active Active
- 2017-03-03 ES ES17760893T patent/ES3039622T3/es active Active
- 2017-03-03 BR BR112018017228-6A patent/BR112018017228A2/pt active IP Right Grant
- 2017-03-03 DK DK17760893.2T patent/DK3423067T3/da active
- 2017-03-03 EP EP24220295.0A patent/EP4538365A3/en active Pending
- 2017-03-03 CA CA3014667A patent/CA3014667A1/en active Pending
- 2017-03-03 EP EP17760893.2A patent/EP3423067B1/en active Active
- 2017-03-03 KR KR1020227012174A patent/KR102481354B1/ko active Active
- 2017-03-03 CN CN201780014836.9A patent/CN109072186B/zh active Active
- 2017-03-03 CN CN202310631766.9A patent/CN116716241A/zh active Pending
- 2017-03-03 WO PCT/US2017/020650 patent/WO2017152044A1/en not_active Ceased
- 2017-03-03 KR KR1020187028393A patent/KR102387896B1/ko active Active
-
2022
- 2022-06-01 JP JP2022089405A patent/JP2022116259A/ja active Pending
- 2022-11-10 AU AU2022268368A patent/AU2022268368B2/en active Active
-
2024
- 2024-03-25 US US18/615,080 patent/US20240415849A1/en active Pending
- 2024-06-19 JP JP2024098418A patent/JP2024116386A/ja active Pending
- 2024-12-04 US US18/968,148 patent/US20250090549A1/en active Pending
- 2024-12-18 AU AU2024278535A patent/AU2024278535A1/en active Pending